Trimel BioPharma Information

Trimel BioPharma Incorporated is now Trimel Pharmaceuticals Corporation. Trimel is a specialty pharmaceutical company actively developing medications for male hypogonadism, female sexual dysfunction, and various respiratory disorders. Trimel holds a licence for the development and marketing rights worldwide, excluding Brazil and Russia, to certain products utilizing a bioadhesive intranasal gel drug delivery technology platform and owns a novel unit-dose dry powder inhaler / nasal dispersion system ("TriVair"). Trimel's drug delivery technology platforms are intended to create products that are expected to be safer, more effective, easier to use and more practical than competitive products on the market. Since its inception, Trimel has focused on the optimization of known high-volume pharmaceutical compounds in order to improve their performace and utilization by physicians and patients. An NDA for CompleoTRT™, a product utilizing Trimel's licensed bioadhesive intranasal gel technology, has been accepted for review by the FDA for regulatory approval in the United States. For more information, please visit www.trimelpharmaceuticals.com.